MovDisordV3, Ncbi, Merge, bibRecord, 004100

MRI Striatal Volumes – A Biomarker for Clinical Trials in HD

Identifieur interne : 004100 ( Ncbi/Merge ); précédent : 004099; suivant : 004101

MRI Striatal Volumes – A Biomarker for Clinical Trials in HD

Auteurs : Elizabeth H. Aylward

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2014.

RBID : PMC:4479278

English descriptors

KwdEn :
- Biological Markers (metabolism), Clinical Trials as Topic (methods), Corpus Striatum (pathology), Humans, Huntington Disease (metabolism), Huntington Disease (pathology), Huntington Disease (therapy), Magnetic Resonance Imaging.
MESH :
- chemical , metabolism : Biological Markers.
- metabolism : Huntington Disease.
- methods : Clinical Trials as Topic.
- pathology : Corpus Striatum, Huntington Disease.
- therapy : Huntington Disease.
- Humans, Magnetic Resonance Imaging.

Abstract

There is an abundance of research showing that MRI striatal volumes decrease long before diagnosis of HD and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are (1) objectively measureable; (2) able to predict known endpoints; and (3) associated with known mechanisms of pathology of the disease. It is recommended that HD researchers consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, as it is anticipated that these measures can contribute significantly in the assessment of treatment effectiveness in HD.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479278

DOI: 10.1002/mds.26013
PubMed: 25164586
PubMed Central: 4479278

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000416
to stream Pmc, to step Curation: 000416
to stream Pmc, to step Checkpoint: 000027
to stream PubMed, to step Corpus: 000403
to stream PubMed, to step Curation: 000403
to stream PubMed, to step Checkpoint: 000535

Links to Exploration step

PMC:4479278

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MRI Striatal Volumes – A Biomarker for Clinical Trials in
HD</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H." last="Aylward">Elizabeth H. Aylward</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25164586</idno>
<idno type="pmc">4479278</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479278</idno>
<idno type="RBID">PMC:4479278</idno>
<idno type="doi">10.1002/mds.26013</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000416</idno>
<idno type="wicri:Area/Pmc/Curation">000416</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000027</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000403</idno>
<idno type="wicri:Area/PubMed/Curation">000403</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000535</idno>
<idno type="wicri:Area/Ncbi/Merge">004100</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">MRI Striatal Volumes – A Biomarker for Clinical Trials in
HD</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H." last="Aylward">Elizabeth H. Aylward</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biological Markers (metabolism)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Corpus Striatum (pathology)</term>
<term>Humans</term>
<term>Huntington Disease (metabolism)</term>
<term>Huntington Disease (pathology)</term>
<term>Huntington Disease (therapy)</term>
<term>Magnetic Resonance Imaging</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biological Markers</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Magnetic Resonance Imaging</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">There is an abundance of research showing that MRI striatal volumes
decrease long before diagnosis of HD and closely track disease progression.
Additional research indicates that these volumetric measures meet important
criteria for a biomarker that can be used in clinical trials: They are (1)
objectively measureable; (2) able to predict known endpoints; and (3) associated
with known mechanisms of pathology of the disease. It is recommended that HD
researchers consider formal application to regulatory agencies for biomarker
status of volumetric MRI striatal measures, as it is anticipated that these
measures can contribute significantly in the assessment of treatment
effectiveness in HD.</p>
</div>
</front>
</TEI>
<double pmid="25164586"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MRI Striatal Volumes – A Biomarker for Clinical Trials in
HD</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H." last="Aylward">Elizabeth H. Aylward</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25164586</idno>
<idno type="pmc">4479278</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479278</idno>
<idno type="RBID">PMC:4479278</idno>
<idno type="doi">10.1002/mds.26013</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000416</idno>
<idno type="wicri:Area/Pmc/Curation">000416</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000027</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">MRI Striatal Volumes – A Biomarker for Clinical Trials in
HD</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H." last="Aylward">Elizabeth H. Aylward</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">There is an abundance of research showing that MRI striatal volumes
decrease long before diagnosis of HD and closely track disease progression.
Additional research indicates that these volumetric measures meet important
criteria for a biomarker that can be used in clinical trials: They are (1)
objectively measureable; (2) able to predict known endpoints; and (3) associated
with known mechanisms of pathology of the disease. It is recommended that HD
researchers consider formal application to regulatory agencies for biomarker
status of volumetric MRI striatal measures, as it is anticipated that these
measures can contribute significantly in the assessment of treatment
effectiveness in HD.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H" last="Aylward">Elizabeth H. Aylward</name>
<affiliation wicri:level="2"><nlm:affiliation>Seattle Children's Research Institute, Seattle, Washington, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Seattle Children's Research Institute, Seattle, Washington</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25164586</idno>
<idno type="pmid">25164586</idno>
<idno type="doi">10.1002/mds.26013</idno>
<idno type="wicri:Area/PubMed/Corpus">000403</idno>
<idno type="wicri:Area/PubMed/Curation">000403</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000535</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.</title>
<author><name sortKey="Aylward, Elizabeth H" sort="Aylward, Elizabeth H" uniqKey="Aylward E" first="Elizabeth H" last="Aylward">Elizabeth H. Aylward</name>
<affiliation wicri:level="2"><nlm:affiliation>Seattle Children's Research Institute, Seattle, Washington, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Seattle Children's Research Institute, Seattle, Washington</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biological Markers (metabolism)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Corpus Striatum (pathology)</term>
<term>Humans</term>
<term>Huntington Disease (metabolism)</term>
<term>Huntington Disease (pathology)</term>
<term>Huntington Disease (therapy)</term>
<term>Magnetic Resonance Imaging</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biological Markers</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Magnetic Resonance Imaging</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are 1) objectively measureable; 2) able to predict known endpoints; and 3) associated with known mechanisms of pathology of the disease. Researchers should consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, because these measures are anticipated to contribute significantly in the assessment of treatment effectiveness in HD.</div>
</front>
</TEI>
</pubmed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004100 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004100 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     PMC:4479278
   |texte=   MRI Striatal Volumes – A Biomarker for Clinical Trials in
HD
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:25164586" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

MRI Striatal Volumes – A Biomarker for Clinical Trials in HD

MRI Striatal Volumes – A Biomarker for Clinical Trials in HD

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki